Fatty liver drug trial in HIV patients ends early

NCT ID NCT05211284

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times

Summary

This study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people living with HIV. The goal was to see if it could reduce liver fat compared to a placebo. The trial was stopped early and only enrolled 4 participants, so no conclusions can be drawn.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Zydus US001

    Durham, North Carolina, 27710, United States

  • Zydus US002

    Indianapolis, Indiana, 46202, United States

  • Zydus US003

    Baltimore, Maryland, 21287, United States

  • Zydus US004

    Birmingham, Alabama, 35294-2050, United States

  • Zydus US005

    La Jolla, California, 92037, United States

  • Zydus US006

    San Francisco, California, 94143, United States

  • Zydus US007

    Houston, Texas, 77030, United States

  • Zydus US008

    Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.